Zobrazeno 1 - 10
of 123
pro vyhledávání: '"Paul A, Rejto"'
Autor:
Yeon Hee Park, Seock-Ah Im, Kyunghee Park, Ji Wen, Kyung-Hun Lee, Yoon-La Choi, Won-Chul Lee, Ahrum Min, Vinicius Bonato, Seri Park, Sripad Ram, Dae-Won Lee, Ji-Yeon Kim, Su Kyeong Lee, Won-Woo Lee, Jisook Lee, Miso Kim, Hyun Seon Kim, Scott L. Weinrich, Han Suk Ryu, Tae Yong Kim, Stephen Dann, Yu-Jin Kim, Diane R. Fernandez, Jiwon Koh, Shuoguo Wang, Song Yi Park, Shibing Deng, Eric Powell, Rupesh Kanchi Ravi, Jadwiga Bienkowska, Paul A. Rejto, Woong-Yang Park, Zhengyan Kan
Publikováno v:
Genome Medicine, Vol 15, Iss 1, Pp 1-18 (2023)
Abstract Background Cyclin-dependent kinase 4/6 inhibitor (CDK4/6) therapy plus endocrine therapy (ET) is an effective treatment for patients with hormone receptor-positive/human epidermal receptor 2-negative metastatic breast cancer (HR+/HER2− MBC
Externí odkaz:
https://doaj.org/article/e43bea5e36154033b3975c0ba6d40d38
Autor:
Zhou Zhu, Nicholas C. Turner, Sherene Loi, Fabrice André, Miguel Martin, Véronique Diéras, Karen A. Gelmon, Nadia Harbeck, Cathy Zhang, Joan Q. Cao, Zhengming Yan, Dongrui R. Lu, Ping Wei, Todd L. VanArsdale, Paul A. Rejto, Xin Huang, Hope S. Rugo, Sibylle Loibl, Massimo Cristofanilli, Richard S. Finn, Yuan Liu
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-10 (2022)
Abstract While cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, combined with endocrine therapy (ET), are becoming the standard-of-care for hormone receptor–positive/human epidermal growth factor receptor 2‒negative metasta
Externí odkaz:
https://doaj.org/article/43b2f5ee4b6d4217b08f6a0227d829bb
Autor:
Yeon Hee Park, Samir Lal, Jeong Eon Lee, Yoon-La Choi, Ji Wen, Sripad Ram, Ying Ding, Soo-Hyeon Lee, Eric Powell, Se Kyung Lee, Jong Han Yu, Keith A. Ching, Jae-Yong Nam, Seok Won Kim, Seok Jin Nam, Ji-Yeon Kim, Soo Youn Cho, Seri Park, Jinho Kim, Soohyn Hwang, Yu Jin Kim, Vinicius Bonato, Diane Fernandez, Shibing Deng, Shuoguo Wang, Hyuntae Shin, Eun-Suk Kang, Woong-Yang Park, Paul A. Rejto, Jadwiga Bienkowska, Zhengyan Kan
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
Neoadjuvant chemotherapy is a therapeutic option for the treatment of breast cancer. Here, the authors characterize changes in the gene expression profiles and immune microenvironment in serial breast cancer biopsies taken before, during and after ne
Externí odkaz:
https://doaj.org/article/d34ef5fb3216481893b451cd685dff30
Autor:
Wenyan Zhong, Jeremy S. Myers, Fang Wang, Kai Wang, Justin Lucas, Edward Rosfjord, Judy Lucas, Andrea T. Hooper, Sharon Yang, Lu Anna Lemon, Magali Guffroy, Chad May, Jadwiga R. Bienkowska, Paul A. Rejto
Publikováno v:
BMC Genomics, Vol 21, Iss 1, Pp 1-17 (2020)
Abstract Background The clinical success of immune checkpoint inhibitors demonstrates that reactivation of the human immune system delivers durable responses for some patients and represents an exciting approach for cancer treatment. An important cla
Externí odkaz:
https://doaj.org/article/8611614a41274bc88abf31f1a71b7264
Autor:
Shibing Deng, Maruja Lira, Donghui Huang, Kai Wang, Crystal Valdez, Jennifer Kinong, Paul A. Rejto, Jadwiga Bienkowska, James Hardwick, Tao Xie
Publikováno v:
BMC Bioinformatics, Vol 19, Iss 1, Pp 1-7 (2018)
Abstract Background Ultra-deep next-generation sequencing of circulating tumor DNA (ctDNA) holds great promise as a tool for the early detection of cancer and for monitoring disease progression and therapeutic responses. However, the low abundance of
Externí odkaz:
https://doaj.org/article/2a29b2d994f64e8d83cd250baf282277
Autor:
Adam Pavlicek, James G. Christensen, Julie L.C. Kan, Paul A. Rejto, Xianxian Zheng, Stephanie T. Shi, Mark Ozeck, Jingjing Ye, Jing Yuan, Joan Cao, Nathan V. Lee, Keith A. Ching, Maruja E. Lira, Scott J. Garza, Kenneth E. Hook
PDF file - 162K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59505128af96dcff2c1992c9bb324cba
https://doi.org/10.1158/1535-7163.22497895
https://doi.org/10.1158/1535-7163.22497895
Autor:
Adam Pavlicek, James G. Christensen, Julie L.C. Kan, Paul A. Rejto, Xianxian Zheng, Stephanie T. Shi, Mark Ozeck, Jingjing Ye, Jing Yuan, Joan Cao, Nathan V. Lee, Keith A. Ching, Maruja E. Lira, Scott J. Garza, Kenneth E. Hook
PDF file - 67K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::663ab03a49d1284de3f301f6aeb309b3
https://doi.org/10.1158/1535-7163.22497904.v1
https://doi.org/10.1158/1535-7163.22497904.v1
Autor:
James G. Christensen, Julie L.C. Kan, Paul A. Rejto, Xianxian Zheng, Jing Yuan, Stephanie T. Shi, Mark Ozeck, Kenneth E. Hook, Scott J. Garza, Joan Cao, Jingjing Ye, Keith A. Ching, Nathan V. Lee, Maruja E. Lira, Adam Pavlicek
PDF file - 62K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::354978a3328f5bcbed208873c8b13a88
https://doi.org/10.1158/1535-7163.22498519
https://doi.org/10.1158/1535-7163.22498519
Autor:
James G. Christensen, Julie L.C. Kan, Paul A. Rejto, Xianxian Zheng, Jing Yuan, Stephanie T. Shi, Mark Ozeck, Kenneth E. Hook, Scott J. Garza, Joan Cao, Jingjing Ye, Keith A. Ching, Nathan V. Lee, Maruja E. Lira, Adam Pavlicek
PDF file - 266K, Single agent and combination activity of figitumumab and correlation of combination synergy with the genetic status of major cancer drivers or RNA expression of cancer drivers and IGF pathway alterations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b049d7a7991201845ad09fde32bc33a
https://doi.org/10.1158/1535-7163.22498522
https://doi.org/10.1158/1535-7163.22498522
Autor:
James G. Christensen, Julie L.C. Kan, Paul A. Rejto, Xianxian Zheng, Jing Yuan, Stephanie T. Shi, Mark Ozeck, Kenneth E. Hook, Scott J. Garza, Joan Cao, Jingjing Ye, Keith A. Ching, Nathan V. Lee, Maruja E. Lira, Adam Pavlicek
PDF file - 20K, Gene notations and ABI assay identifiers.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b0a360ab114877eeafc890143bb6d64
https://doi.org/10.1158/1535-7163.22498510
https://doi.org/10.1158/1535-7163.22498510